171 related articles for article (PubMed ID: 38256106)
21. Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells.
Khera N; Rajkumar AS; Abdulkader M Alkurdi K; Liu Z; Ma H; Waseem A; Teh MT
Mol Cancer; 2023 Sep; 22(1):146. PubMed ID: 37667354
[TBL] [Abstract][Full Text] [Related]
22. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt.
Kuo SZ; Blair KJ; Rahimy E; Kiang A; Abhold E; Fan JB; Wang-Rodriguez J; Altuna X; Ongkeko WM
BMC Cancer; 2012 Nov; 12():556. PubMed ID: 23176396
[TBL] [Abstract][Full Text] [Related]
23. Multi-Omics Identification of Genetic Alterations in Head and Neck Squamous Cell Carcinoma and Therapeutic Efficacy of HNC018 as a Novel Multi-Target Agent for c-MET/STAT3/AKT Signaling Axis.
Khedkar HN; Chen LC; Kuo YC; Wu ATH; Huang HS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373393
[TBL] [Abstract][Full Text] [Related]
24. TRPM7 via calcineurin/NFAT pathway mediates metastasis and chemotherapeutic resistance in head and neck squamous cell carcinoma.
Chen TM; Huang CM; Hsieh MS; Lin CS; Lee WH; Yeh CT; Liu SC
Aging (Albany NY); 2022 Jun; 14(12):5250-5270. PubMed ID: 35771152
[TBL] [Abstract][Full Text] [Related]
25. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
[TBL] [Abstract][Full Text] [Related]
26. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
[TBL] [Abstract][Full Text] [Related]
27. A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma.
Tong T; Qin X; Jiang Y; Guo H; Wang X; Li Y; Xie F; Lu H; Zhai P; Ma H; Zhang J
BMC Med; 2022 Jul; 20(1):231. PubMed ID: 35773668
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion.
Sarnella A; Ferrara Y; Auletta L; Albanese S; Cerchia L; Alterio V; De Simone G; Supuran CT; Zannetti A
J Exp Clin Cancer Res; 2022 Apr; 41(1):122. PubMed ID: 35365193
[TBL] [Abstract][Full Text] [Related]
29. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
30. Suppression of head and neck cancer cell survival and cisplatin resistance by GRP78 small molecule inhibitor YUM70.
Yamamoto V; Wang B; Lee AS
Front Oncol; 2022; 12():1044699. PubMed ID: 36713577
[TBL] [Abstract][Full Text] [Related]
31. Cultivation of Head and Neck Squamous Cell Carcinoma Cells with Wound Fluid Leads to Cisplatin Resistance via Epithelial-Mesenchymal Transition Induction.
Meyer TJ; Stöth M; Moratin H; Ickrath P; Herrmann M; Kleinsasser N; Hagen R; Hackenberg S; Scherzad A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922946
[TBL] [Abstract][Full Text] [Related]
32. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract][Full Text] [Related]
33. The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response.
De Azevedo J; Mourtada J; Bour C; Devignot V; Schultz P; Borel C; Pencreach E; Mellitzer G; Gaiddon C; Jung AC
Cells; 2022 Sep; 11(18):. PubMed ID: 36139440
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.
Zheng Y; Dou H; Li Q; Sun Y; Wang Y; Zhang W
Cancer Control; 2021; 28():1073274821997444. PubMed ID: 34029149
[TBL] [Abstract][Full Text] [Related]
35. VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells.
Chen T; Yang F; Dai X; Yu Y; Sun Y; Wu X; Li R; Zhou Q
Curr Cancer Drug Targets; 2023; 23(6):482-495. PubMed ID: 36748213
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
[TBL] [Abstract][Full Text] [Related]
37. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
[TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
40. DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
Martens-de Kemp SR; Dalm SU; Wijnolts FM; Brink A; Honeywell RJ; Peters GJ; Braakhuis BJ; Brakenhoff RH
PLoS One; 2013; 8(4):e61555. PubMed ID: 23613873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
